Marketed under the brand name Vyloy, the drug is to be used with fluoropyrimidine- and platinum-based chemotherapy in adults with advanced cancer of the stomach or gastroesophageal junction (GEJ ...

“He's a perfect example of somebody who's living his best life with his cancer,” said Dr. Stephanie Snow, a medical ...

"While there have been advances in the first-line treatment of locally advanced unresectable and metastatic gastric and GEJ cancers in the last several years, there is still a tremendous unmet ...

Symptoms of stomach cancer can often be confused with less serious conditions, which is why it's vital to be aware of the warning signs and seek medical advice early. One particular painful ...

VYLOY is the first and only CLDN18.2-targeted treatment approved in the U.S. for adults with advanced gastric and gastroesophageal junction cancer whose tumors are CLDN18.2 positive In the ...

About 64% of Hispanic adults receive a late diagnosis of advanced stomach cancer, compared with 57% of white adults. Likewise, 34% of Hispanic adults and 42% of Black adults are diagnosed with ...

Data suggest that cabozantinib and pembrolizumab can be effective in patients with advanced gastric or gastroesophageal junction cancer whose disease is resistant or refractory to immune checkpoint ...

Ferroptosis offers new strategies to combat treatment resistance in digestive tract cancers, enhancing the efficacy of ...